

Supplementary material

Journal: Clinical Drug Investigation

Hospitalization Rates and Therapy Costs of German Schizophrenia Patients who are Initiated on Long-acting Injectable Medication: A Mirror-Image Study

Authors: Jörg Mahlich^{1,2}, Kerstin Olbrich¹, Adrian Wilk³, Antonie Wimmer⁴, Claus Wolff-Menzler⁵

¹ Health Economics and Outcomes Research, Janssen, Pharmaceutical Companies of Johnson & Johnson, Neuss, Germany

² Düsseldorf Institute of Competition Economics (DICE); University of Düsseldorf, Germany

³ Team Gesundheit, Gesellschaft für Gesundheitsmanagement mbH, Essen, Germany

⁴ Medical Affairs, Janssen, Pharmaceutical Companies of Johnson & Johnson, Neuss, Germany

⁵ Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Georg-August-University, Göttingen, Germany

Corresponding author:

Jörg Mahlich,

Health Economics and Outcomes Research,

Janssen, Pharmaceutical Companies of Johnson & Johnson,

Neuss, Germany

Email: joerg.mahlich@gmail.com

Phone: +49 173 7361945

Table 1: ICD-10 codes used to diagnose schizophrenia

ICD-10 code	Schizophrenia subtype
F20.0	Paranoid schizophrenia
F20.1	Hebephrenic schizophrenia
F20.2	Catatonic schizophrenia
F20.3	Undifferentiated schizophrenia
F20.4	Post-schizophrenic depression
F20.5	Residual schizophrenia
F20.6	Simple schizophrenia
F20.8	Other schizophrenia
F20.9	Schizophrenia, unspecified

Abbreviations: ICD-10 - International Classification of Diseases, 10th Revision

Table 2: ICD-10 Codes for comorbidities

Comorbidity	ICD-10 code
Myocardial infarction	I21.x, I22.x, I25.2
Congestive heart failure	I09.9, I11.0, I13.0, I13.2, I25.5, I42.0, I42.5–I42.9, I43.x, I50.x, P29.0
Peripheral vascular disease	I70.x, I71.x, I73.1, I73.8, I73.9, I77.1, I79.0, I79.2, K55.1, K55.8, K55.9, Z95.8, Z95.9
Cerebrovascular disease	G45.x, G46.x, H34.0, I60.x–I69.x
Dementia	F00.x–F03.x, F05.1, G30.x, G31.1
Chronic pulmonary disease	I27.8, I27.9, J40.x–J47.x, J60.x–J67.x, J68.4, J70.1, J70.3
Rheumatic disease	M05.x, M06.x, M31.5, M32.x–M34.x, M35.1, M35.3, M36.0
Peptic ulcer disease	K25.x–K28.x
Mild liver disease	B18.x, K70.0–K70.3, K70.9, K71.3–K71.5, K71.7, K73.x, K74.x, K76.0, K76.2–K76.4, K76.8, K76.9, Z94.4
Diabetes without chronic complication	E10.0, E10.1, E10.6, E10.8, E10.9, E11.0, E11.1, E11.6, E11.8, E11.9, E12.0, E12.1, E12.6, E12.8, E12.9, E13.0, E13.1, E13.6, E13.8, E13.9, E14.0, E14.1, E14.6, E14.8, E14.9
Diabetes with chronic complication	E10.2–E10.5, E10.7, E11.2–E11.5, E11.7, E12.2–E12.5, E12.7, E13.2–E13.5, E13.7, E14.2–E14.5, E14.7
Hemiplegia or paraplegia	G04.1, G11.4, G80.1, G80.2, G81.x, G82.x, G83.0–G83.4, G83.9
Renal disease	I12.0, I13.1, N03.2–N03.7, N05.2–N05.7, N18.x, N19.x, N25.0, Z49.0–Z49.2, Z94.0, Z99.2
Tumors without metastasis	C00.x–C26.x, C30.x–C34.x, C37.x–C41.x, C43.x, C45.x–C58.x, C60.x–C76.x
Lymphoma	C81.x–C85.x, C88.x
Leukemia	C90.x–C97.x
Moderate or severe liver disease	I85.0, I85.9, I86.4, I98.2, K70.4, K71.1, K72.1, K72.9, K76.5, K76.6, K76.7
Metastatic solid tumor	C77.x–C80.x
AIDS/HIV	B20.x–B22.x, B24.x

Abbreviations: AIDS – Acquired Immunodeficiency Syndrome, HIV – Human Immunodeficiency Virus, ICD-10 - International Classification of Diseases, 10th Revision

Table 3: Medication characteristics and changes from pre-index to post-index period

Parameter	First generation antipsychotics						Second generation antipsychotics			
	Overall (n=850)	Fluphenazine (n=35)	Haloperidol (n=96)	Flupentixol (n=129)	Zuclopenthixol (n=19)	Fluspirilene (n=76)	Olanzapine (n=23)	Risperidone (n=176)	Aripiprazole (n=66)	Paliperidone (n=230)
Dose of first LAI prescription (mg), mean (SD)	119.7 (129.0)	102.9 (92.2)	202.6 (199.3)	84.3 (73.4)	144.7 (22.9)	5.6 (5.2)	347.6 (72.5)	38.5 (10.3)	386.4 (34.6)	106.1 (32.0)
Dose of second LAI prescription among patients with second prescription (mg), mean (SD)	120.0 (126.6)	64.3 (51.0)	199.3 (199.4)	73.8 (66.3)	150.0 (0.0)	6.8 (5.3)	335.5 (74.4)	39.2 (9.9)	381.8 (38.9)	100.7 (28.8)
Number of days between first and second prescription among patients with second prescription, mean (SD)	61.4 (74.2)	82.3 (91.3)	147.5 (93.4)	88.4 (83.2)	91.1 (80.3)	127.0 (98.0)	15.3 (20.6)	50.2 (51.9)	23.9 (28.1)	26.2 (31.0)
Number of injections of initial agent, mean (SD)										
During post-index period	12.3 (10.3)	14.5 (14.0)	11.6 (9.9)	16.1 (15.0)	18.3 (10.8)	6.3 (6.5)	12.3 (8.0)	16.5 (10.7)	8.5 (5.2)	9.5 (5.0)
During post-index period until switch to other LAI	12.2 (10.3)	14.5 (14.0)	11.5 (9.8)	16.0 (15.0)	16.2 (10.0)	6.3 (6.5)	11.7 (8.1)	16.3 (10.7)	8.5 (5.2)	9.5 (5.0)
Number of injections of initial agent during post-index period until switch to other LAI, n (%)										
1	89 (10.5)	8 (22.9)	11 (11.5)	17 (13.2)	1 (5.3)	9 (11.8)	4 (17.4)	8 (4.5)	10 (15.2)	21 (9.1)
2	48 (5.6)	0 (0.0)	9 (9.4)	8 (6.2)	0 (0.0)	5 (6.6)	0 (0.0)	6 (3.4)	6 (9.1)	14 (6.1)
3	44 (5.2)	2 (5.7)	3 (3.1)	5 (3.9)	0 (0.0)	18 (23.7)	0 (0.0)	5 (2.8)	2 (3.0)	9 (3.9)
4-6	156 (18.4)	5 (14.3)	19 (19.8)	21 (16.3)	5 (26.3)	26 (34.2)	4 (17.4)	37 (21.0)	7 (10.6)	32 (13.9)
7-10	102 (12.0)	3 (8.6)	14 (14.6)	13 (10.1)	2 (10.5)	8 (10.5)	1 (4.3)	20 (11.4)	11 (16.7)	30 (13.0)
11-20	261 (30.7)	7 (20.0)	26 (27.1)	24 (18.6)	3 (15.8)	6 (7.9)	11 (47.8)	30 (17.0)	30 (45.5)	124 (53.9)
21+	150 (17.6)	10 (28.6)	14 (14.6)	41 (31.8)	8 (42.1)	4 (5.3)	3 (13.0)	70 (39.8)	0 (0.0)	0 (0.0)
Number of prescriptions of initial agent, mean (SD)										
During post-index period	5.2 (4.4)	3.1 (2.6)	2.8 (1.7)	3.7 (2.9)	3.7 (2.1)	1.8 (1.4)	10.0 (7.4)	5.1 (4.3)	7.2 (4.7)	7.7 (4.5)

During post-index period until switch to other LAI	5.1 (4.4)	3.1 (2.6)	2.8 (1.7)	3.6 (2.9)	3.3 (1.9)	1.8 (1.4)	9.7 (7.6)	5.0 (4.3)	7.1 (4.7)	7.7 (4.5)
Number of prescriptions of initial agent during post-index period until switch to other LAI, n (%)										
1	201 (23.6)	14 (40.0)	23 (24.0)	37 (28.7)	5 (26.3)	45 (59.2)	6 (26.1)	32 (18.2)	11 (16.7)	28 (12.2)
2	112 (13.2)	4 (11.4)	27 (28.1)	18 (14.0)	3 (15.8)	17 (22.4)	0 (0.0)	20 (11.4)	7 (10.6)	16 (7.0)
3	81 (9.5)	6 (17.1)	18 (18.8)	19 (14.7)	3 (15.8)	6 (7.9)	1 (4.3)	14 (8.0)	2 (3.0)	12 (5.2)
4-6	221 (26.0)	6 (17.1)	25 (26.0)	43 (33.3)	8 (42.1)	7 (9.2)	2 (8.7)	7 (43.8)	9 (13.6)	44 (19.1)
7-10	108 (12.7)	4 (11.4)	3 (3.1)	7 (5.4)	0 (0.0)	1 (1.3)	2 (8.7)	20 (11.4)	18 (27.3)	53 (23.0)
11-20	121 (14.2)	1 (2.9)	0 (0.0)	5 (3.9)	0 (0.0)	0 (0.0)	10 (43.5)	9 (5.1)	19 (28.8)	77 (33.5)
21+	6 (0.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (8.7)	4 (2.3)	0 (0.0)	0 (0.0)
Number of patients with at least 1 prescription, n (%)	586 (68.9)	18 (51.4)	57 (59.4)	90 (69.8)	11 (57.9)	38 (50.0)	16 (69.6)	136 (77.3)	50 (75.8)	170 (73.9)
Last prescribed agent during pre-index period, n (%)										
Levomepromazine	12 (1.4)	1 (2.9)	3 (3.1)	3 (2.3)	0 (0.0)	2 (2.6)	0 (0.0)	2 (1.1)	0 (0.0)	1 (0.4)
Fluphenazine	3 (0.4)	2 (5.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.6)	0 (0.0)	0 (0.0)
Perazine	15 (1.8)	1 (2.9)	2 (2.1)	3 (2.3)	1 (5.3)	4 (5.3)	0 (0.0)	1 (0.6)	0 (0.0)	3 (1.3)
Haloperidol	24 (2.8)	0 (0.0)	11 (11.5)	1 (0.8)	0 (0.0)	1 (1.3)	0 (0.0)	4 (2.3)	0 (0.0)	7 (3.0)
Melperone	12 (1.4)	1 (2.9)	5 (5.2)	1 (0.8)	1 (5.3)	2 (2.6)	0 (0.0)	2 (1.1)	0 (0.0)	0 (0.0)
Pipamperone	21 (2.5)	1 (2.9)	2 (2.1)	3 (2.3)	0 (0.0)	0 (0.0)	1 (4.3)	2 (1.1)	2 (3.0)	10 (4.3)
Ziprasidone	6 (0.7)	0 (0.0)	0 (0.0)	1 (0.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.6)	1 (1.5)	3 (1.3)
Flupentixol	27 (3.2)	0 (0.0)	0 (0.0)	21 (16.3)	1 (5.3)	0 (0.0)	0 (0.0)	2 (1.1)	2 (3.0)	1 (0.4)
Chlorprothixene	21 (2.5)	1 (2.9)	2 (2.1)	5 (3.9)	0 (0.0)	2 (2.6)	0 (0.0)	6 (3.4)	0 (0.0)	5 (2.2)
Zuclopenthixol	3 (0.4)	0 (0.0)	0 (0.0)	2 (1.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.4)
Clozapine	36 (4.2)	3 (8.6)	6 (6.3)	6 (4.7)	1 (5.3)	2 (2.6)	1 (4.3)	6 (3.4)	3 (4.5)	8 (3.5)
Olanzapine	57 (6.7)	1 (2.9)	8 (8.3)	9 (7.0)	3 (15.8)	1 (1.3)	11 (47.8)	7 (4.0)	3 (4.5)	14 (6.1)
Quetiapine	76 (8.9)	3 (8.6)	9 (9.4)	10 (7.8)	0 (0.0)	6 (7.9)	1 (4.3)	12 (6.8)	4 (6.1)	31 (13.5)
Sulpiride	2 (0.2)	0 (0.0)	0 (0.0)	1 (0.8)	0 (0.0)	1 (1.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Tiapride	1 (0.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Amisulpride	36 (4.2)	3 (8.6)	3 (3.1)	7 (5.4)	0 (0.0)	4 (5.3)	2 (8.7)	6 (3.4)	4 (6.1)	7 (3.0)
Lithium	6 (0.7)	0 (0.0)	1 (1.0)	2 (1.6)	1 (5.3)	0 (0.0)	0 (0.0)	1 (0.6)	1 (1.5)	0 (0.0)
Prothipendyl	10 (1.2)	0 (0.0)	0 (0.0)	1 (0.8)	0 (0.0)	1 (1.3)	0 (0.0)	3 (1.7)	2 (3.0)	3 (1.3)
Risperidone	146 (17.2)	1 (2.9)	2 (2.1)	7 (5.4)	3 (15.8)	7 (9.2)	0 (0.0)	71 (40.3)	2 (3.0)	53 (23.0)
Aripiprazole	65 (7.6)	0 (0.0)	3 (3.1)	5 (3.9)	0 (0.0)	4 (5.3)	0 (0.0)	9 (5.1)	26 (39.4)	18 (7.8)
Agents used during pre-index period, n (%)										

Levomepromazine	31 (3.6)	2 (5.7)	5 (5.2)	7 (5.4)	2 (10.5)	4 (5.3)	0 (0.0)	3 (1.7)	1 (1.5)	7 (3.0)
Fluphenazine	7 (0.8)	3 (8.6)	0 (0.0)	1 (0.8)	1 (5.3)	0 (0.0)	0 (0.0)	1 (0.6)	1 (1.5)	0 (0.0)
Perphenazine	3 (0.4)	0 (0.0)	0 (0.0)	2 (1.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.4)
Perazine	26 (3.1)	2 (5.7)	2 (2.1)	6 (4.7)	1 (5.3)	5 (6.6)	0 (0.0)	5 (2.8)	0 (0.0)	5 (2.2)
Haloperidol	48 (5.6)	0 (0.0)	18 (18.8)	2 (1.6)	1 (5.3)	3 (3.9)	0 (0.0)	10 (5.7)	2 (3.0)	12 (5.2)
Melperone	26 (3.1)	1 (2.9)	8 (8.3)	4 (3.1)	1 (5.3)	4 (5.3)	0 (0.0)	3 (1.7)	1 (1.5)	4 (1.7)
Pipamperone	44 (5.2)	1 (2.9)	5 (5.2)	7 (5.4)	1 (5.3)	2 (2.6)	1 (4.3)	7 (4.0)	2 (3.0)	18 (7.8)
Bromperidol	2 (0.2)	0 (0.0)	0 (0.0)	2 (1.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Benperidol	8 (0.9)	0 (0.0)	1 (1.0)	4 (3.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (1.3)
Ziprasidone	21 (2.5)	0 (0.0)	2 (2.1)	2 (1.6)	0 (0.0)	0 (0.0)	0 (0.0)	7 (4.0)	1 (1.5)	9 (3.9)
Flupentixol	50 (5.9)	1 (2.9)	0 (0.0)	32 (24.8)	1 (5.3)	0 (0.0)	0 (0.0)	6 (3.4)	2 (3.0)	8 (3.5)
Chlorprothixene	58 (6.8)	1 (2.9)	2 (2.1)	16 (12.4)	1 (5.3)	4 (5.3)	0 (0.0)	18 (10.2)	1 (1.5)	15 (6.5)
Zuclopenthixol	12 (1.4)	0 (0.0)	0 (0.0)	2 (1.6)	2 (10.5)	0 (0.0)	0 (0.0)	4 (2.3)	0 (0.0)	4 (1.7)
Pimozide	1 (0.1)	0 (0.0)	1 (1.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Clozapine	55 (6.5)	4 (11.4)	8 (8.3)	7 (5.4)	2 (10.5)	2 (2.6)	2 (8.7)	9 (5.1)	4 (6.1)	17 (7.4)
Olanzapine	130 (15.3)	2 (5.7)	10 (10.4)	19 (14.7)	4 (21.1)	5 (6.6)	14 (60.9)	21 (11.9)	13 (19.7)	42 (18.3)
Quetiapine	183 (21.5)	4 (11.4)	17 (17.7)	24 (18.6)	1 (5.3)	12 (15.8)	3 (13.0)	36 (20.5)	17 (25.8)	69 (30.0)
Asenapine	5 (0.6)	0 (0.0)	2 (2.1)	2 (1.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.4)
Sulpiride	3 (0.4)	0 (0.0)	0 (0.0)	1 (0.8)	0 (0.0)	1 (1.3)	0 (0.0)	1 (0.6)	0 (0.0)	0 (0.0)
Tiapride	3 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.3)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.4)
Amisulpride	65 (7.6)	3 (8.6)	6 (6.3)	12 (9.3)	1 (5.3)	5 (6.6)	2 (8.7)	16 (9.1)	6 (9.1)	14 (6.1)
Lithium	16 (1.9)	1 (2.9)	1 (1.0)	2 (1.6)	1 (5.3)	0 (0.0)	0 (0.0)	4 (2.3)	2 (3.0)	5 (2.2)
Prothipendyl	23 (2.7)	1 (2.9)	0 (0.0)	4 (3.1)	0 (0.0)	1 (1.3)	0 (0.0)	6 (3.4)	2 (3.0)	9 (3.9)
Risperidone	205 (24.1)	1 (2.9)	3 (3.1)	13 (10.1)	4 (21.1)	8 (10.5)	0 (0.0)	88 (50.0)	7 (10.6)	81 (35.2)
Aripiprazole	124 (14.6)	1 (2.9)	7 (7.3)	9 (7.0)	2 (10.5)	6 (7.9)	1 (4.3)	22 (12.5)	38 (57.6)	38 (16.5)
Agents used during post-index period, n (%)										
Levomepromazine	35 (4.1)	1 (2.9)	2 (2.1)	8 (6.2)	4 (21.1)	3 (3.9)	0 (0.0)	7 (4.0)	1 (1.5)	9 (3.9)
Fluphenazine	39 (4.6)	35 (100.0)	0 (0.0)	0 (0.0)	1 (5.3)	1 (1.3)	0 (0.0)	0 (0.0)	0 (0.0)	2 (0.9)
Perphenazine	2 (0.2)	0 (0.0)	0 (0.0)	1 (0.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)	0 (0.0)
Perazine	38 (4.5)	2 (5.7)	3 (3.1)	11 (8.5)	0 (0.0)	6 (7.9)	0 (0.0)	8 (4.5)	0 (0.0)	8 (3.5)
Haloperidol	140 (16.5)	2 (5.7)	96 (100.0)	3 (2.3)	5 (26.3)	1 (1.3)	1 (4.3)	14 (8.0)	1 (1.5)	17 (7.4)
Melperone	37 (4.4)	1 (2.9)	7 (7.3)	5 (3.9)	1 (5.3)	2 (2.6)	0 (0.0)	9 (5.1)	2 (3.0)	10 (4.3)
Pipamperone	73 (8.6)	4 (11.4)	4 (4.2)	13 (10.1)	2 (10.5)	4 (5.3)	3 (13.0)	13 (7.4)	10 (15.2)	20 (8.7)
Benperidol	8 (0.9)	1 (2.9)	0 (0.0)	2 (1.6)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.6)	1 (1.5)	3 (1.3)
Ziprasidone	17 (2.0)	1 (2.9)	3 (3.1)	3 (2.3)	0 (0.0)	1 (1.3)	0 (0.0)	5 (2.8)	0 (0.0)	4 (1.7)
Flupentixol	166 (19.5)	1 (2.9)	1 (1.0)	129 (100.0)	0 (0.0)	4 (5.3)	1 (4.3)	11 (6.3)	6 (9.1)	13 (5.7)
Chlorprothixene	74 (8.7)	5 (14.3)	4 (4.2)	12 (9.3)	2 (10.5)	4 (5.3)	3 (13.0)	19 (10.8)	4 (6.1)	21 (9.1)
Zuclopenthixol	37 (4.4)	0 (0.0)	1 (1.0)	6 (4.7)	19 (100.0)	0 (0.0)	0 (0.0)	6 (3.4)	1 (1.5)	4 (1.7)

Pimozide	77 (9.1)	0 (0.0)	0 (0.0)	1 (0.8)	0 (0.0)	76 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Clozapine	3 (0.4)	0 (0.0)	1 (1.0)	0 (0.0)	0 (0.0)	2 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Olanzapine	53 (6.2)	3 (8.6)	7 (7.3)	6 (4.7)	1 (5.3)	2 (2.6)	1 (4.3)	10 (5.7)	2 (3.0)	21 (9.1)
Quetiapine	128 (15.1)	6 (17.1)	9 (9.4)	20 (15.5)	3 (15.8)	6 (7.9)	23 (100.0)	16 (9.1)	13 (19.7)	32 (13.9)
Asenapine	179 (21.1)	3 (8.6)	14 (14.6)	27 (20.9)	2 (10.5)	15 (19.7)	1 (4.3)	38 (21.6)	15 (22.7)	64 (27.8)
Sulpiride	4 (0.5)	0 (0.0)	0 (0.0)	2 (1.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (0.9)
Amisulpride	43 (5.1)	0 (0.0)	2 (2.1)	10 (7.8)	2 (10.5)	5 (6.6)	1 (4.3)	8 (4.5)	3 (4.5)	12 (5.2)
Lithium	20 (2.4)	1 (2.9)	2 (2.1)	3 (2.3)	1 (5.3)	1 (1.3)	0 (0.0)	5 (2.8)	2 (3.0)	5 (2.2)
Prothipendyl	32 (3.8)	1 (2.9)	1 (1.0)	3 (2.3)	1 (5.3)	1 (1.3)	1 (4.3)	8 (4.5)	4 (6.1)	12 (5.2)
Risperidone	281 (33.1)	3 (8.6)	4 (4.2)	19 (14.7)	2 (10.5)	14 (18.4)	0 (0.0)	176 (100.0)	7 (10.6)	56 (24.3)
Aripiprazole	164 (19.3)	3 (8.6)	9 (9.4)	10 (7.8)	1 (5.3)	5 (6.6)	7 (30.4)	20 (11.4)	66 (100.0)	43 (18.7)
Paliperidone	262 (30.8)	0 (0.0)	3 (3.1)	2 (1.6)	3 (15.8)	0 (0.0)	2 (8.7)	19 (10.8)	3 (4.5)	230 (100.0)
LAI used during post-index period, n (%)										
Fluphenazine	36 (4.2)	35 (100.0)	0 (0.0)	0 (0.0)	1 (5.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Haloperidol	99 (11.6)	1 (2.9)	96 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.4)
Flupentixol	150 (17.6)	1 (2.9)	0 (0.0)	129 (100.0)	0 (0.0)	3 (3.9)	1 (4.3)	7 (4.0)	2 (3.0)	7 (3.0)
Zuclopenthixol	22 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	19 (100.0)	0 (0.0)	0 (0.0)	3 (1.7)	0 (0.0)	0 (0.0)
Fluspirilene	77 (9.1)	0 (0.0)	0 (0.0)	1 (0.8)	0 (0.0)	76 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Olanzapine	26 (3.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	23 (100.0)	0 (0.0)	2 (3.0)	1 (0.4)
Risperidone	184 (21.6)	0 (0.0)	0 (0.0)	4 (3.1)	0 (0.0)	0 (0.0)	0 (0.0)	176 (100.0)	0 (0.0)	4 (1.7)
Aripiprazole	79 (9.3)	0 (0.0)	1 (1.0)	1 (0.8)	1 (5.3)	0 (0.0)	4 (17.4)	3 (1.7)	66 (100.0)	3 (1.3)
Paliperidone	262 (30.8)	0 (0.0)	3 (3.1)	2 (1.6)	3 (15.8)	0 (0.0)	2 (8.7)	19 (10.8)	3 (4.5)	230 (100.0)

Medications that were used <1% in any group were not added in the table but are listed here as per the parameter. In last prescribed agent during pre-index period – perphenazine, thioridazine, bromperidol, benperidol, sertindole, fluspirilene, pimozide, asenapine, zotepine, and paliperidone; in agents used during pre-index period – thioridazine, sertindole, fluspirilene, zotepine, and paliperidone; in agents used during post-index period – thioridazine, bromperidol, sertindole, tiapride, and zotepine; and in LAI during post-index period – perphenazine.

Abbreviations: LAI – Long-acting Injectable, SD – Standard Deviation

Table 4: Change in number of hospitalized patients from pre-index to post-index period

Parameter		First generation antipsychotics					Second generation antipsychotics				
		Overall (n=850)	Fluphenazine (n=35)	Haloperidol (n=96)	Flupentixol (n=129)	Zuclopenthixol (n=19)	Fluspirilene (n=76)	Olanzapine (n=23)	Risperidone (n=176)	Aripiprazole (n=66)	Paliperidone (n=230)
Number of patients with at least 1 hospitalization as per Model 1, n (%)											
All hospitalized patients	Pre-index	638 (75.1)	18 (51.4)	58 (60.4)	88 (68.2)	11 (57.9)	30 (39.5)	22 (95.7)	146 (83.0)	57 (86.4)	208 (90.4)
	Post-index	564 (66.4)	19 (54.3)	51 (53.1)	86 (66.7)	11 (57.9)	34 (44.7)	17 (73.9)	130 (73.9)	47 (71.2)	169 (73.5)
Non-psychiatric inpatients	Pre-index	154 (18.1)	7 (20.0)	20 (20.8)	22 (17.1)	2 (10.5)	19 (25.0)	2 (8.7)	32 (18.2)	6 (9.1)	44 (19.1)
	Post-index	131 (15.4)	9 (25.7)	19 (19.8)	30 (23.3)	2 (10.5)	20 (26.3)	2 (8.7)	23 (13.1)	3 (4.5)	23 (10.0)
Non-psychiatric outpatients	Pre-index	45 (5.3)	1 (2.9)	4 (4.2)	5 (3.9)	2 (10.5)	6 (7.9)	2 (8.7)	9 (5.1)	3 (4.5)	13 (5.7)
	Post-index	39 (4.6)	0 (0.0)	2 (2.1)	8 (6.2)	0 (0.0)	7 (9.2)	2 (8.7)	11 (6.3)	1 (1.5)	8 (3.5)
Psychiatric inpatients	Pre-index	511 (60.1)	15 (42.9)	37 (38.5)	62 (48.1)	8 (42.1)	8 (10.5)	21 (91.3)	127 (72.2)	49 (74.2)	184 (80.0)
	Post-index	265 (31.2)	9 (25.7)	19 (19.8)	40 (31.0)	8 (42.1)	11 (14.5)	6 (26.1)	66 (37.5)	22 (33.3)	84 (36.5)
Psychiatric outpatients	Pre-index	343 (40.4)	10 (28.6)	25 (26.0)	52 (40.3)	5 (26.3)	5 (6.6)	14 (60.9)	82 (46.6)	34 (51.5)	116 (50.4)
	Post-index	364 (42.8)	13 (37.1)	22 (22.9)	52 (40.3)	6 (31.6)	5 (6.6)	15 (65.2)	92 (52.3)	40 (60.6)	119 (51.7)
Number of patients with at least 1 hospitalization as per Model 2, n (%)											
All hospitalized patients	Pre-index	609 (71.6)	18 (51.4)	57 (59.4)	81 (62.8)	11 (57.9)	30 (39.5)	21 (91.3)	140 (79.5)	51 (77.3)	200 (87.0)
	Post-index	564 (66.4)	19 (54.3)	51 (53.1)	86 (66.7)	11 (57.9)	34 (44.7)	17 (73.9)	130 (73.9)	47 (71.2)	169 (73.5)
Non-psychiatric inpatients	Pre-index	154 (18.1)	7 (20.0)	20 (20.8)	22 (17.1)	2 (10.5)	19 (25.0)	2 (8.7)	32 (18.2)	6 (9.1)	44 (19.1)
	Post-index	131 (15.4)	9 (25.7)	19 (19.8)	30 (23.3)	2 (10.5)	20 (26.3)	2 (8.7)	23 (13.1)	3 (4.5)	23 (10.0)
Non-psychiatric outpatients	Pre-index	41 (4.8)	1 (2.9)	4 (4.2)	4 (3.1)	2 (10.5)	6 (7.9)	2 (8.7)	7 (4.0)	3 (4.5)	12 (5.2)
	Post-index	39 (4.6)	0 (0.0)	2 (2.1)	8 (6.2)	0 (0.0)	7 (9.2)	2 (8.7)	11 (6.3)	1 (1.5)	8 (3.5)
Psychiatric inpatients	Pre-index	464 (54.6)	15 (42.9)	36 (37.5)	55 (42.6)	8 (42.1)	8 (10.5)	19 (82.6)	117 (66.5)	40 (60.6)	166 (72.2)
	Post-index	265 (31.2)	9 (25.7)	19 (19.8)	40 (31.0)	8 (42.1)	11 (14.5)	6 (26.1)	66 (37.5)	22 (33.3)	84 (36.5)
Psychiatric outpatients	Pre-index	279 (32.8)	8 (22.9)	23 (24.0)	44 (34.1)	5 (26.3)	5 (6.6)	6 (26.1)	68 (38.6)	28 (42.4)	92 (40.0)
	Post-index	364 (42.8)	13 (37.1)	22 (22.9)	52 (40.3)	6 (31.6)	5 (6.6)	15 (65.2)	92 (52.3)	40 (60.6)	119 (51.7)

Table 5: Change in number of patients using ambulatory healthcare resources from pre-index to post-index period

		First generation antipsychotics					Second generation antipsychotics				
Parameter		Overall (n=850)	Fluphenazine (n=35)	Haloperidol (n=96)	Flupentixol (n=129)	Zuclopenthixol (n=19)	Fluspirilene (n=76)	Olanzapine (n=23)	Risperidone (n=176)	Aripiprazole (n=66)	Paliperidone (n=230)
Number of patients with visits, n (%)	Pre-index	812 (95.5)	33 (94.3)	91 (94.8)	124 (96.1)	19 (100.0)	76 (100.0)	21 (91.3)	169 (96.0)	60 (90.9)	219 (95.2)
	Post-index	828 (97.4)	34 (97.1)	93 (96.9)	126 (97.7)	18 (94.7)	76 (100.0)	22 (95.7)	170 (96.6)	65 (98.5)	224 (97.4)
Number of patients with specialist visits, n (%)											
General practitioner	Pre-index	754 (88.7)	31 (88.6)	84 (87.5)	114 (88.4)	18 (94.7)	73 (96.1)	20 (87.0)	157 (89.2)	54 (81.8)	203 (88.3)
	Post-index	754 (88.7)	32 (91.4)	85 (88.5)	118 (91.5)	16 (84.2)	73 (96.1)	20 (87.0)	159 (90.3)	54 (81.8)	197 (85.7)
Neurology and psychiatry	Pre-index	525 (61.8)	22 (62.9)	71 (74.0)	87 (67.4)	12 (63.2)	47 (61.8)	12 (52.2)	104 (59.1)	32 (48.5)	138 (60.0)
	Post-index	541 (63.6)	26 (74.3)	76 (79.2)	96 (74.4)	15 (78.9)	53 (69.7)	12 (52.2)	93 (52.8)	35 (53.0)	135 (58.7)
Ophthalmology	Pre-index	142 (16.7)	8 (22.9)	26 (27.1)	22 (17.1)	2 (10.5)	20 (26.3)	2 (8.7)	21 (11.9)	9 (13.6)	32 (13.9)
	Post-index	144 (16.9)	8 (22.9)	25 (26.0)	21 (16.3)	2 (10.5)	21 (27.6)	2 (8.7)	26 (14.8)	10 (15.2)	29 (12.6)
Orthopaedics	Pre-index	133 (15.6)	5 (14.3)	17 (17.7)	29 (22.5)	1 (5.3)	22 (28.9)	0 (0.0)	32 (18.2)	7 (10.6)	20 (8.7)
	Post-index	153 (18.0)	5 (14.3)	22 (22.9)	30 (23.3)	3 (15.8)	26 (34.2)	1 (4.3)	26 (14.8)	6 (9.1)	34 (14.8)
Gynaecology	Pre-index	174 (20.5)	7 (20.0)	21 (21.9)	32 (24.8)	3 (15.8)	28 (36.8)	0 (0.0)	31 (17.6)	13 (19.7)	39 (17.0)
	Post-index	190 (22.4)	5 (14.3)	19 (19.8)	33 (25.6)	4 (21.1)	32 (42.1)	1 (4.3)	33 (18.8)	15 (22.7)	48 (20.9)
Otorhinolaryngology	Pre-index	156 (18.4)	3 (8.6)	25 (26.0)	27 (20.9)	2 (10.5)	28 (36.8)	2 (8.7)	31 (17.6)	8 (12.1)	30 (13.0)
	Post-index	152 (17.9)	7 (20.0)	20 (20.8)	24 (18.6)	2 (10.5)	25 (32.9)	0 (0.0)	28 (15.9)	9 (13.6)	37 (16.1)
Dermatologist	Pre-index	143 (16.8)	8 (22.9)	13 (13.5)	15 (11.6)	2 (10.5)	17 (22.4)	3 (13.0)	35 (19.9)	9 (13.6)	41 (17.8)
	Post-index	136 (16.0)	8 (22.9)	12 (12.5)	17 (13.2)	1 (5.3)	17 (22.4)	2 (8.7)	32 (18.2)	10 (15.2)	37 (16.1)
Internist	Pre-index	50 (5.9)	0 (0.0)	11 (11.5)	11 (8.5)	0 (0.0)	7 (9.2)	0 (0.0)	13 (7.4)	2 (3.0)	6 (2.6)
	Post-index	65 (7.6)	2 (5.7)	11 (11.5)	12 (9.3)	2 (10.5)	11 (14.5)	1 (4.3)	10 (5.7)	5 (7.6)	11 (4.8)
Laboratory medicine	Pre-index	309 (36.4)	15 (42.9)	32 (33.3)	53 (41.1)	10 (52.6)	31 (40.8)	6 (26.1)	58 (33.0)	22 (33.3)	82 (35.7)
	Post-index	362 (42.6)	13 (37.1)	35 (36.5)	55 (42.6)	12 (63.2)	41 (53.9)	10 (43.5)	72 (40.9)	25 (37.9)	99 (43.0)
Radiology	Pre-index	138 (16.2)	6 (17.1)	14 (14.6)	21 (16.3)	4 (21.1)	24 (31.6)	0 (0.0)	29 (16.5)	9 (13.6)	31 (13.5)
	Post-index	117 (13.8)	2 (5.7)	11 (11.5)	21 (16.3)	2 (10.5)	26 (34.2)	2 (8.7)	21 (11.9)	9 (13.6)	23 (10.0)
Urology	Pre-index	74 (8.7)	5 (14.3)	17 (17.7)	14 (10.9)	1 (5.3)	11 (14.5)	1 (4.3)	9 (5.1)	4 (6.1)	12 (5.2)

Psychological psychotherapist	Post- index	69 (8.1)	3 (8.6)	12 (12.5)	13 (10.1)	2 (10.5)	11 (14.5)	0 (0.0)	11 (6.3)	2 (3.0)	15 (6.5)
	Pre-index	39 (4.6)	0 (0.0)	2 (2.1)	9 (7.0)	0 (0.0)	7 (9.2)	0 (0.0)	9 (5.1)	3 (4.5)	9 (3.9)
Other	Post- index	46 (5.4)	0 (0.0)	3 (3.1)	7 (5.4)	0 (0.0)	7 (9.2)	0 (0.0)	7 (4.0)	8 (12.1)	14 (6.1)
	Pre-index	309 (36.4)	12 (34.3)	39 (40.6)	52 (40.3)	12 (63.2)	37 (48.7)	3 (13.0)	66 (37.5)	19 (28.8)	69 (30.0)
Unknown	Post- index	308 (36.2)	12 (34.3)	30 (31.3)	44 (34.1)	9 (47.4)	40 (52.6)	7 (30.4)	62 (35.2)	22 (33.3)	82 (35.7)
	Pre-index	288 (33.9)	8 (22.9)	33 (34.4)	49 (38.0)	4 (21.1)	36 (47.4)	8 (34.8)	60 (34.1)	19 (28.8)	71 (30.9)
	Post- index	240 (28.2)	9 (25.7)	30 (31.3)	34 (26.4)	5 (26.3)	31 (40.8)	6 (26.1)	56 (31.8)	16 (24.2)	53 (23.0)

Table 6: Change in employment among patients with member status from pre-index to post-index period

		First generation antipsychotics					Second generation antipsychotics				
Parameter		Overall (n=850)	Fluphenazine (n=35)	Haloperidol (n=96)	Flupentixol (n=129)	Zuclopenthixol (n=19)	Fluspirilene (n=76)	Olanzapine (n=23)	Risperidone (n=176)	Aripiprazole (n=66)	Paliperidone (n=230)
Number of patients with member status, n (%)	Pre-index	772 (90.8)	31 (88.6)	89 (92.7)	115 (89.1)	16 (84.2)	67 (88.2)	21 (91.3)	164 (93.2)	58 (87.9)	211 (91.7)
	Post-index	775 (91.2)	31 (88.6)	90 (93.8)	117 (90.7)	16 (84.2)	67 (88.2)	21 (91.3)	162 (92.0)	60 (90.9)	211 (91.7)
Number of patients with unemployment, n (%)	Pre-index	203 (26.3)	2 (6.5)	11 (12.4)	17 (14.8)	2 (12.5)	8 (11.9)	6 (28.6)	58 (35.4)	20 (34.5)	79 (37.4)
	Post-index	210 (27.1)	2 (6.5)	11 (12.2)	19 (16.2)	2 (12.5)	9 (13.4)	6 (28.6)	57 (35.2)	23 (38.3)	81 (38.4)
Length of unemployment in months, mean (SD)	Pre-index	2.4 (4.5)	0.8 (3.0)	1.1 (3.1)	1.4 (3.6)	0.9 (3.0)	1.0 (3.0)	2.3 (4.4)	3.2 (4.9)	3.3 (5.0)	3.5 (5.1)
	Post-index	2.4 (4.5)	0.7 (2.9)	1.1 (3.3)	1.4 (3.7)	1.5 (4.1)	1.0 (2.8)	3.2 (5.3)	3.0 (4.7)	3.6 (5.3)	3.5 (5.1)
	P value	0.710	1	0.915	0.542	1	0.945	0.313	0.288	0.274	0.768
Number of patients with switch from unemployment to employment, n (%)	Pre-index	35 (4.5)	0 (0.0)	3 (3.4)	4 (3.5)	0 (0.0)	1 (1.5)	2 (9.5)	12 (7.3)	3 (5.2)	10 (4.7)
	Post-index	23 (3.0)	0 (0.0)	1 (1.1)	3 (2.6)	0 (0.0)	1 (1.5)	1 (4.8)	5 (3.1)	2 (3.3)	10 (4.7)
Number of patients with switch from employment to unemployment, n (%)	Pre-index	35 (4.5)	0 (0.0)	3 (3.4)	4 (3.5)	0 (0.0)	0 (0.0)	1 (4.8)	7 (4.3)	6 (10.3)	14 (6.6)
	Post-index	36 (4.6)	0 (0.0)	2 (2.2)	5 (4.3)	0 (0.0)	2 (3.0)	0 (0.0)	9 (5.6)	3 (5.0)	15 (7.1)

Abbreviations: SD – Standard Deviation

Table 7: Change in aids from pre-index to post-index period

		First generation antipsychotics						Second generation antipsychotics			
Parameter		Overall (n=850)	Fluphenazine (n=35)	Haloperidol (n=96)	Flupentixol (n=129)	Zuclopenthixol (n=19)	Fluspirilene (n=76)	Olanzapine (n=23)	Risperidone (n=176)	Aripiprazole (n=66)	Paliperidone (n=230)
Number of patients with aids, n (%)	Pre-index	10 (1.2)	0 (0.0)	3 (3.1)	1 (0.8)	1 (5.3)	1 (1.3)	0 (0.0)	0 (0.0)	2 (3.0)	2 (0.9)
	Post-index	5 (0.6)	0 (0.0)	1 (1.0)	0 (0.0)	1 (5.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (1.3)
Number of aids, mean (SD)	Pre-index	0.0 (0.5)	0.0 (0.0)	0.1 (0.7)	0.0 (0.1)	0.1 (0.2)	0.0 (0.1)	0.0 (0.0)	0.0 (0.0)	0.1 (0.8)	0.1 (0.7)
	Post-index	0.0 (0.2)	0.0 (0.0)	0.0 (0.2)	0.0 (0.0)	0.1 (0.2)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.4)
	P value	0.023	1	0.250	1	1	1	1	1	0.500	1
Costs, mean (SD)	Pre-index	2.0 (20.1)	0.0 (0.0)	5.3 (31.7)	0.7 (7.5)	5.3 (22.9)	1.1 (9.8)	0.0 (0.0)	0.0 (0.0)	6.4 (37.1)	2.0 (23.9)
	Post-index	0.6 (9.1)	0.0 (0.0)	1.4 (13.4)	0.0 (0.0)	1.8 (8.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	0.0 (0.0)	1.7 (15.1)
	P value	0.014	1	0.250	1	1	1	1	1	0.500	1

Abbreviations: SD – Standard Deviation

Table 8: Change in therapies from pre-index to post-index period

		First generation antipsychotics					Second generation antipsychotics				
Parameter		Overall (n=850)	Fluphenazine (n=35)	Haloperidol (n=96)	Flupentixol (n=129)	Zuclopenthixol (n=19)	Fluspirilene (n=76)	Olanzapine (n=23)	Risperidone (n=176)	Aripiprazole (n=66)	Paliperidone (n=230)
Number of patients with utilization, n (%)											
Biperiden	Pre-index	108 (12.7)	4 (11.4)	20 (20.8)	21 (16.3)	4 (21.1)	7 (9.2)	1 (4.3)	22 (12.5)	3 (4.5)	26 (11.3)
	Post-index	162 (19.1)	8 (22.9)	25 (26.0)	35 (27.1)	5 (26.3)	9 (11.8)	2 (8.7)	33 (18.8)	7 (10.6)	38 (16.5)
Lorazepam	Pre-index	92 (10.8)	4 (11.4)	10 (10.4)	18 (14.0)	2 (10.5)	9 (11.8)	0 (0.0)	18 (10.2)	8 (12.1)	23 (10.0)
	Post-index	115 (13.5)	8 (22.9)	12 (12.5)	18 (14.0)	5 (26.3)	11 (14.5)	3 (13.0)	25 (14.2)	9 (13.6)	24 (10.4)
Psychiatric interview, consulting (single treatment)	Pre-index	443 (52.1)	20 (57.1)	54 (56.3)	73 (56.6)	10 (52.6)	38 (50.0)	11 (47.8)	88 (50.0)	31 (47.0)	118 (51.3)
	Post-index	486 (57.2)	21 (60.0)	63 (65.6)	84 (65.1)	12 (63.2)	48 (63.2)	12 (52.2)	87 (49.4)	34 (51.5)	125 (54.3)
Electroencephalography	Pre-index	70 (8.2)	3 (8.6)	3 (3.1)	10 (7.8)	0 (0.0)	4 (5.3)	0 (0.0)	17 (9.7)	6 (9.1)	27 (11.7)
	Post-index	40 (4.7)	4 (11.4)	3 (3.1)	9 (7.0)	0 (0.0)	2 (2.6)	0 (0.0)	9 (5.1)	3 (4.5)	10 (4.3)
Elaborate diagnostics	Pre-index	52 (6.1)	1 (2.9)	8 (8.3)	9 (7.0)	0 (0.0)	0 (0.0)	3 (13.0)	8 (4.5)	7 (10.6)	16 (7.0)
	Post-index	17 (2.0)	1 (2.9)	0 (0.0)	7 (5.4)	1 (5.3)	0 (0.0)	1 (4.3)	2 (1.1)	1 (1.5)	4 (1.7)
Number of times utilized, mean (SD)											
Biperiden	Pre-index	0.4 (1.3)	0.2 (0.8)	0.6 (1.4)	0.5 (1.4)	0.7 (1.5)	0.3 (1.1)	0.7 (3.3)	0.4 (1.4)	0.1 (0.4)	0.3 (1.0)
	Post-index	0.6 (1.7)	0.6 (1.6)	1.2 (2.7)	0.8 (1.6)	1.0 (1.9)	0.4 (1.2)	0.7 (2.6)	0.6 (1.5)	0.2 (0.6)	0.5 (1.5)
	P value	<0.001	0.078	<0.001	0.003	0.406	0.230	1	0.165	0.246	0.044
Lorazepam	Pre-index	0.4 (1.7)	0.2 (0.5)	0.4 (1.4)	0.7 (2.4)	0.2 (0.7)	0.8 (2.6)	0.0 (0.0)	0.4 (1.9)	0.2 (0.8)	0.2 (1.2)
	Post-index	0.6 (2.5)	1.0 (2.7)	0.4 (1.4)	0.9 (3.6)	1.9 (5.2)	0.9 (3.1)	0.7 (2.2)	0.5 (2.5)	0.4 (1.4)	0.4 (1.7)
	P value	<0.001	0.086	0.667	0.503	0.344	0.478	0.250	0.087	0.301	0.143
Psychiatric interview,	Pre-	3.1 (4.8)	3.3 (4.2)	3.4 (5.4)	3.8 (5.3)	2.8 (4.9)	4.1 (6.3)	2.4 (3.3)	2.9 (5.4)	2.4 (3.6)	2.6 (3.7)

Baseline characteristics											
Intervention	Control	Outcome									
		Pre-index	Post-index	Pre-index	Post-index	Pre-index	Post-index	Pre-index	Post-index	Pre-index	Post-index
consulting (single treatment)	index	Pre-index	Post-index	Pre-index	Post-index	Pre-index	Post-index	Pre-index	Post-index	Pre-index	Post-index
		P	P	P	P	P	P	P	P	P	P
		value	value	value	value	value	value	value	value	value	value
Electroencephalography	Pre-index	4.7 (6.7)	4.1 (5.5)	4.2 (4.8)	5.7 (8.3)	6.1 (6.6)	5.8 (7.7)	3.7 (4.6)	4.7 (7.7)	3.7 (5.6)	4.5 (5.8)
		<0.001	0.395	0.032	<0.001	0.002	0.001	0.058	<0.001	0.016	<0.001
		0.1 (0.3)	0.1 (0.4)	0.0 (0.2)	0.1 (0.3)	0.0 (0.0)	0.1 (0.2)	0.0 (0.0)	0.1 (0.3)	0.1 (0.3)	0.1 (0.4)
Elaborate diagnostics	Post-index	0.1 (0.3)	0.2 (0.6)	0.0 (0.2)	0.1 (0.3)	0.0 (0.0)	0.0 (0.2)	0.0 (0.0)	0.1 (0.2)	0.0 (0.2)	0.1 (0.3)
		0.001	0.688	1	0.791	1	0.688	1	0.083	0.453	0.002
		0.1 (0.4)	0.0 (0.2)	0.1 (0.4)	0.1 (0.3)	0.0 (0.0)	0.0 (0.0)	0.1 (0.3)	0.1 (0.3)	0.2 (0.7)	0.1 (0.4)
Treatment utilization, n (%)	Standard treatment, adults	0.0 (0.3)	0.2 (1.4)	0.0 (0.0)	0.1 (0.2)	0.1 (0.2)	0.0 (0.0)	0.0 (0.2)	0.0 (0.1)	0.0 (0.1)	0.0 (0.2)
		<0.001	1	0.008	0.590	1	1	0.625	0.035	0.031	0.011
		Pre-index	Post-index	Pre-index	Post-index	Pre-index	Post-index	Pre-index	Post-index	Pre-index	Post-index
Number of times treatment was utilized, mean (SD)	Standard treatment, adults	392 (46.1)	12 (34.3)	28 (29.2)	40 (31.0)	6 (31.6)	7 (9.2)	18 (78.3)	99 (56.3)	38 (57.6)	144 (62.6)
		214 (25.2)	8 (22.9)	15 (15.6)	33 (25.6)	4 (21.1)	8 (10.5)	5 (21.7)	52 (29.5)	20 (30.3)	69 (30.0)
		327 (38.5)	9 (25.7)	29 (30.2)	45 (34.9)	5 (26.3)	1 (1.3)	15 (65.2)	84 (47.7)	21 (31.8)	118 (51.3)
	Intensive treatment, adults	156 (18.4)	5 (14.3)	10 (10.4)	30 (23.3)	6 (31.6)	5 (6.6)	3 (13.0)	43 (24.4)	12 (18.2)	42 (18.3)
		Pre-index	Post-index	Pre-index	Post-index	Pre-index	Post-index	Pre-index	Post-index	Pre-index	Post-index
		2.7 (4.2)	2.1 (3.9)	1.5 (2.8)	1.8 (3.9)	2.0 (3.8)	0.6 (2.1)	5.3 (6.2)	3.3 (4.3)	3.4 (4.7)	3.7 (4.5)
	Standard treatment, adults	1.3 (3.0)	1.6 (4.0)	0.6 (2.0)	1.2 (3.0)	0.6 (1.5)	0.3 (1.0)	2.0 (4.4)	1.6 (3.1)	1.5 (3.1)	1.6 (3.3)
		<0.001	0.599	0.003	0.093	0.063	0.371	0.014	<0.001	0.001	<0.001
		1.6 (2.9)	1.0 (2.1)	1.4 (2.6)	1.8 (3.1)	1.2 (2.5)	0.0 (0.2)	2.7 (3.2)	2.3 (3.7)	1.3 (2.5)	1.9 (2.5)
	Intensive treatment, adults	0.7 (1.9)	0.9 (2.7)	0.3 (0.8)	0.9 (2.2)	1.6 (2.7)	0.2 (1.1)	0.7 (2.0)	1.0 (2.4)	0.6 (1.6)	0.6 (1.7)
		<0.001	0.864	<0.001	0.003	0.5	0.156	<0.001	<0.001	0.042	<0.001
		Pre-index	Post-index	Pre-index	Post-index	Pre-index	Post-index	Pre-index	Post-index	Pre-index	Post-index

Treatment area utilization, n (%)		value									
General psychiatry	Pre-index	469 (55.2)	14 (40.0)	31 (32.3)	51 (39.5)	8 (42.1)	5 (6.6)	21 (91.3)	119 (67.6)	44 (66.7)	176 (76.5)
	Post-index	240 (28.2)	8 (22.9)	15 (15.6)	32 (24.8)	8 (42.1)	8 (10.5)	6 (26.1)	64 (36.4)	22 (33.3)	77 (33.5)
Standard treatment	Pre-index	365 (42.9)	12 (34.3)	26 (27.1)	38 (29.5)	6 (31.6)	3 (3.9)	20 (87.0)	94 (53.4)	35 (53.0)	131 (57.0)
	Post-index	194 (22.8)	7 (20.0)	13 (13.5)	28 (21.7)	4 (21.1)	5 (6.6)	4 (17.4)	51 (29.0)	16 (24.2)	66 (28.7)
Intensive treatment	Pre-index	306 (36.0)	9 (25.7)	24 (25.0)	36 (27.9)	5 (26.3)	1 (1.3)	15 (65.2)	77 (43.8)	26 (39.4)	113 (49.1)
	Post-index	134 (15.8)	5 (14.3)	8 (8.3)	19 (14.7)	5 (26.3)	4 (5.3)	3 (13.0)	39 (22.2)	11 (16.7)	40 (17.4)
Day hospital	Pre-index	55 (6.5)	1 (2.9)	3 (3.1)	5 (3.9)	1 (5.3)	2 (2.6)	4 (17.4)	12 (6.8)	4 (6.1)	23 (10.0)
	Post-index	32 (3.8)	0 (0.0)	1 (1.0)	3 (2.3)	1 (5.3)	1 (1.3)	3 (13.0)	4 (2.3)	7 (10.6)	12 (5.2)
Addiction	Pre-index	49 (5.8)	0 (0.0)	7 (7.3)	6 (4.7)	0 (0.0)	0 (0.0)	3 (13.0)	17 (9.7)	2 (3.0)	14 (6.1)
	Post-index	25 (2.9)	1 (2.9)	2 (2.1)	8 (6.2)	0 (0.0)	0 (0.0)	1 (4.3)	8 (4.5)	0 (0.0)	5 (2.2)
Standard treatment	Pre-index	26 (3.1)	0 (0.0)	3 (3.1)	1 (0.8)	0 (0.0)	0 (0.0)	2 (8.7)	13 (7.4)	1 (1.5)	6 (2.6)
	Post-index	15 (1.8)	1 (2.9)	2 (2.1)	5 (3.9)	0 (0.0)	0 (0.0)	1 (4.3)	4 (2.3)	0 (0.0)	2 (0.9)
Intensive treatment	Pre-index	40 (4.7)	0 (0.0)	6 (6.3)	4 (3.1)	0 (0.0)	0 (0.0)	3 (13.0)	13 (7.4)	1 (1.5)	13 (5.7)
	Post-index	19 (2.2)	1 (2.9)	1 (1.0)	4 (3.1)	0 (0.0)	0 (0.0)	1 (4.3)	7 (4.0)	0 (0.0)	5 (2.2)
Psychogeriatric	Pre-index	20 (2.4)	0 (0.0)	2 (2.1)	5 (3.9)	0 (0.0)	4 (5.3)	0 (0.0)	4 (2.3)	0 (0.0)	5 (2.2)
	Post-index	14 (1.6)	0 (0.0)	2 (2.1)	4 (3.1)	0 (0.0)	3 (3.9)	0 (0.0)	1 (0.6)	0 (0.0)	4 (1.7)
Standard treatment	Pre-index	14 (1.6)	0 (0.0)	1 (1.0)	4 (3.1)	0 (0.0)	4 (5.3)	0 (0.0)	2 (1.1)	0 (0.0)	3 (1.3)
	Post-index	9 (1.1)	0 (0.0)	1 (1.0)	4 (3.1)	0 (0.0)	2 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	2 (0.9)
Intensive treatment	Pre-index	13 (1.5)	0 (0.0)	2 (2.1)	3 (2.3)	0 (0.0)	1 (1.3)	0 (0.0)	3 (1.7)	0 (0.0)	4 (1.7)

Number of times treatment area was utilized, mean (SD)											
	Post-index	7 (0.8)	0 (0.0)	1 (1.0)	2 (1.6)	0 (0.0)	1 (1.3)	0 (0.0)	1 (0.6)	0 (0.0)	2 (0.9)
General psychiatry	Pre-index	1.5 (2.1)	1.0 (1.6)	1.0 (1.7)	1.2 (2.2)	1.2 (1.7)	0.1 (0.4)	3.6 (3.9)	1.9 (2.1)	1.5 (1.9)	1.9 (1.9)
	Post-index	0.8 (1.8)	1.0 (3.0)	0.3 (0.6)	0.8 (1.8)	0.7 (1.0)	0.2 (0.7)	1.5 (3.5)	1.0 (1.9)	0.8 (1.8)	0.9 (1.7)
	P value	<0.001	0.374	<0.001	0.012	0.266	0.561	<0.001	<0.001	0.006	<0.001
Standard treatment	Pre-index	0.7 (1.2)	0.7 (1.1)	0.4 (0.7)	0.6 (1.5)	0.7 (1.2)	0.0 (0.2)	2.0 (2.2)	0.9 (1.2)	0.8 (1.0)	0.9 (1.1)
	Post-index	0.4 (1.0)	0.5 (1.3)	0.1 (0.4)	0.4 (1.2)	0.4 (0.9)	0.1 (0.3)	0.6 (1.7)	0.5 (1.0)	0.5 (1.2)	0.5 (0.9)
	P value	<0.001	0.42	<0.001	0.12	0.188	0.531	0.001	<0.001	0.021	<0.001
Intensive treatment	Pre-index	0.6 (1.1)	0.3 (0.6)	0.6 (1.2)	0.6 (1.1)	0.4 (0.8)	0.0 (0.1)	1.3 (1.6)	0.8 (1.2)	0.6 (1.0)	0.8 (1.2)
	Post-index	0.3 (0.9)	0.4 (1.5)	0.1 (0.3)	0.3 (0.9)	0.3 (0.5)	0.1 (0.4)	0.6 (1.7)	0.4 (1.2)	0.3 (0.6)	0.3 (0.8)
	P value	<0.001	0.956	<0.001	0.021	0.75	0.313	0.003	<0.001	0.015	<0.001
Day hospital	Pre-index	0.1 (0.4)	0.0 (0.2)	0.0 (0.2)	0.1 (0.4)	0.1 (0.2)	0.1 (0.3)	0.2 (0.4)	0.1 (0.4)	0.1 (0.7)	0.1 (0.5)
	Post-index	0.0 (0.3)	0.0 (0.0)	0.0 (0.2)	0.0 (0.2)	0.1 (0.2)	0.0 (0.1)	0.2 (0.5)	0.0 (0.3)	0.1 (0.3)	0.1 (0.3)
	P value	0.004	1	0.75	0.359	1	0.5	1	0.108	1	0.074
Addiction	Pre-index	0.1 (0.7)	0.0 (0.0)	0.1 (0.5)	0.1 (0.4)	0.0 (0.0)	0.0 (0.0)	0.3 (0.8)	0.3 (1.1)	0.0 (0.2)	0.1 (0.6)
	Post-index	0.1 (0.5)	0.1 (0.5)	0.1 (0.7)	0.1 (0.6)	0.0 (0.0)	0.0 (0.0)	0.1 (0.4)	0.1 (0.5)	0.0 (0.0)	0.0 (0.3)
	P value	0.012	1	0.281	0.313	1	1	0.5	0.013	0.5	0.091
Intensive treatment	Pre-index	0.1 (0.4)	0.0 (0.0)	0.1 (0.4)	0.0 (0.3)	0.0 (0.0)	0.0 (0.0)	0.2 (0.5)	0.1 (0.7)	0.0 (0.1)	0.1 (0.3)
	Post-index	0.0 (0.2)	0.1 (0.3)	0.0 (0.3)	0.1 (0.4)	0.0 (0.0)	0.0 (0.0)	0.0 (0.2)	0.0 (0.2)	0.0 (0.0)	0.0 (0.2)
	P value	0.015	1	0.375	0.797	1	1	0.5	0.047	1	0.12
Psychogeriatric	Pre-	0.1 (0.4)	0.0 (0.0)	0.0 (0.2)	0.1 (0.5)	0.0 (0.0)	0.1 (0.6)	0.0 (0.0)	0.0 (0.2)	0.0 (0.0)	0.1 (0.5)

index										
Post-index	0.0 (0.3)	0.0 (0.0)	0.0 (0.3)	0.1 (0.3)	0.0 (0.0)	0.1 (0.6)	0.0 (0.0)	0.0 (0.1)	0.0 (0.0)	0.0 (0.3)
P										
value	0.2	1	1	0.672	1	0.969	1	0.25	1	0.375

Therapies which were utilized by <1% of the patients or whose mean utilization in both pre-index and post-index periods were not included in the table. These therapies or treatment areas are – disorder due to drugs and drug abuse; psychiatric treatment; psychosocial, psychosomatic, and psychotherapeutic therapy; psychosomatic therapy; complex treatment, psychotherapeutic, adults; complex treatment, psychosomatic and psychotherapeutic, adults; standard treatment, children; standard treatment, young people; intensive treatment, children and young people; rehabilitative, long-standing, and psychotherapy treatment areas in general psychiatry; standard, rehabilitative, long-standing, psychotherapy, and day hospital treatment areas in addiction treatment; standard, intensive, rehabilitative, long-standing, psychotherapy, and day hospital treatment areas in psychogeriatric treatment; standard and intensive treatment in children and young people, and rehabilitative, long-standing, psychotherapy, parent-child, and day hospital treatment areas in child and youth psychiatry.